Datavault AI Inc. has granted Scilex Holding Company an exclusive worldwide license to deploy its proprietary AI-driven technology within the biotech and biopharma sectors. The agreement enables Scilex to build and operate a Biotech Exchange platform that will tokenize, trade, and monetize biotech assets including genomic data, diagnostics, and drug information. This licensing arrangement represents a significant expansion of Datavault AI's technology into the healthcare sector, with expectations that the platform will evolve into a Pharmaceutical Exchange addressing an estimated $2 trillion market opportunity.
The expansion provides companies in the biotech space with potential access to non-dilutive funding through asset tokenization and trading capabilities. The financial terms of the agreement include a $10 million upfront payment to be made in four installments, along with potential milestone payments that could reach up to $2.55 billion. The technology is supported by Datavault AI's broad patent portfolio and proven high-performance computing expertise, which the company has developed across multiple industries.
Datavault AI's platform leverages Web 3.0 technology and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. The company's Information Data Exchange technology enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata objects. More information about the company's technology can be found at https://www.datavaultsite.com.
The technology suite offered by Datavault AI is completely customizable and includes AI and Machine Learning automation, third-party integration, detailed analytics, marketing automation, and advertising monitoring. The platform serves multiple industries including sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, and energy. Additional company information and updates are available at https://ibn.fm/DVLT. This strategic partnership marks a significant step in applying AI-driven blockchain solutions to the biotech industry, potentially transforming how biotech assets are valued, traded, and monetized while providing new funding avenues for companies in the sector.
